Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. - Wikidata - wikimedia - TriplyDB

Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.

Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.

http://www.wikidata.org/entity/Q45086553

about

A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group Genetic studies of a cluster of acute lymphoblastic leukemia cases in Churchill County, Nevada Osteonecrosis in children with acute lymphoblastic leukemia Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia.Microarray‑based screening of differentially expressed genes in glucocorticoid‑induced avascular necrosis.Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL Bone morbidity in childhood leukemia: epidemiology, mechanisms, diagnosis, and treatment Prevalence of osteonecrosis and associated risk factors in children before allogeneic BMT.Improved prognosis for older adolescents with acute lymphoblastic leukemia.Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.Age-dependent changes in health status in the Childhood Cancer Survivor cohort Utility of early screening magnetic resonance imaging for extensive hip osteonecrosis in pediatric patients treated with glucocorticoids.Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors Avascular necrosis in pediatric systemic lupus erythematosus: a brief report and review of the literature.Inherited genetic variation in childhood acute lymphoblastic leukemia.Screening and management of adverse endocrine outcomes in adult survivors of childhood and adolescent cancer.Ancestry and pharmacogenetics of antileukemic drug toxicity Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse Model Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia Pharmacogenomics of adverse effects of anti-leukemic agents in children.Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial Unique MRI findings as an early predictor of osteonecrosis in pediatric acute lymphoblastic leukemia.Osteonecrosis in children after therapy for malignancy.Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.Vertebral compression fractures during chemotherapy for childhood acute lymphoblastic leukemia: commentary on a report from the STeroid Associated Osteoporosis in the Pediatric Population (STOPP) research program.The pharmacogenetics research network: from SNP discovery to clinical drug response.Incidence and outcome of osteonecrosis in children and adolescents after intensive therapy for acute lymphoblastic leukemia (ALL).Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations.Milestones in the curability of pediatric cancers Pharmacogenetics of acute lymphoblastic leukemia treatment response.Risk factors for symptomatic osteonecrosis in childhood ALL: A retrospective study of a Slovenian pediatric ALL population between 1970 and 2004.The adolescent and young adult with cancer: state of the art-- acute leukemias.Pharmacogenetics in acute lymphoblastic leukemia.Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings.Chronic health conditions in childhood cancer survivors: is it all treatment-related--or do genetics play a role?Assessment of corticosteroid-induced osteonecrosis in children undergoing chemotherapy for acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.Pharmacogenomics of pediatric acute lymphoblastic leukemia.

P2860

Q24656610-BE1B86A1-EE0C-48CC-BD7D-D53FDBC6C4BC Q24682265-A030E5D6-9E18-479C-A01E-03D4D7003FDE Q28066799-19732A72-C9D4-4A7C-B2F2-5C9BD6C3A1D6 Q28068930-9E86046B-5746-4531-AA36-C7ED58EFF286 Q28083449-0BD93D2B-E1B9-4E2E-8A14-AFB7EAEFCCE9 Q28087637-C39C7411-CDCD-4A4C-8D81-F19EAB55D7AE Q33398162-19CEC5F2-E251-4FDC-8755-CFBE05940D2D Q33702066-2ED33543-62EF-4B6D-9CD9-DA9E807AE9A8 Q33925128-4FFC2D33-045A-44DA-987D-46790CC06C26 Q34038283-C897D49F-FF4C-487B-8B2E-814393DD99C4 Q34440965-7E888047-6702-4D2E-A18D-23E6256E80C1 Q34679298-8EEF432E-1592-4CB6-95B2-B7371BF91A9D Q34707586-E225BD5F-28D0-4917-AC61-638C8ED373EB Q35040691-54429B1B-99DA-4732-9263-92FFE935D354 Q35065477-BD4601AB-65FE-4C4A-8A7F-FD2BA698A063 Q35327266-5185B27D-56BE-4D53-ABE3-9290699DB0EF Q35555709-2F6C2E24-B568-4F95-BF9C-22E5D80F850B Q35784497-8A349E28-CC8D-4127-B507-2439AB798243 Q35815806-A7EAA9DF-3E3C-4CCF-90DD-583CFFA53281 Q35828717-82D3105C-588D-452F-BE4B-D83D3CC8C246 Q35954058-EFF0D8F6-EAAA-4C80-A3C7-6B31ABF28A96 Q36143232-2B4DB15C-BE66-4EC9-882B-F50C772ADF4C Q36191097-D2AD36C3-1773-4CCE-9B19-C38D70C1A00B Q36251056-0C7B69B9-34BC-49DE-BECA-00EB0319C4F6 Q36422310-5F752591-C3F1-4FEA-9C65-6934D54433C7 Q36429353-5773A48C-ABB0-4F8E-A642-58D40DFB48DD Q36452241-81494B78-C1C1-464A-A060-1F9C5F371841 Q36508158-0D05EF8A-BEE9-4E6A-B1F7-73D37476F146 Q36752662-659BDEAE-9EDB-470B-9CF4-C595E6D69ABB Q36895136-846942BF-AB33-41C9-95C2-811BDF841E66 Q36909252-5F00CAA6-B3A1-4832-AE3E-5F49BB17DDEE Q36925083-FAD38F1E-3DEC-495C-8A20-CC667AFCC429 Q36968156-9522A065-B292-46BA-B2B0-B59E1F36AC89 Q37106645-98B03CD2-0161-40B9-AF33-576081719C3C Q37134753-063DEE87-26C1-4548-BA35-35F9ABAA3E3D Q37150913-59EEF589-2241-4409-A53E-DFB290B7F30C Q37181682-048099CE-4FC4-4D9E-86A1-6B618945396F Q37390119-84561544-A8BA-4672-B008-ED7FA843C168 Q37414183-DC9897B4-9D05-4F14-A5B8-083D6B089908 Q37739432-00E771AA-B582-42FC-A4EF-3CF6A23F422A

P2860

Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.

http://www.wikidata.org/entity/Q45086553

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.

@en

Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.

@nl

type

label

Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.

@en

Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.

@nl

prefLabel

Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.

@en

Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.

@nl

P1433

Q45086553-83302D77-9969-4EEE-91C8-430F6DC2EF0B

P1476

Q45086553-2B677252-84DF-4B94-9ADA-23E94EF597FE

P2093

Q45086553-247EB16F-5ED8-434B-8F2B-2364402C38D8

Q45086553-2C1E7506-D7C6-41A3-A498-46EA8B2B5938

Q45086553-35E9361B-1EAA-4BB7-A51E-F3BBB1A7700F

Q45086553-56DBC265-2C72-4D6E-8E80-43DF18077BB1

Q45086553-780079EB-127A-4DC1-B292-7F14A7595AF2

Q45086553-7D1D95B2-B79E-49F3-855E-CACF96BF11F5

Q45086553-A5561E16-E46D-410F-A965-3661FBE0B3B3

Q45086553-A7273AEB-1445-445E-83F3-457AAEB68011

Q45086553-A9677536-1C45-4C58-8926-6CB4DC4AA9A0

P304

Q45086553-ACB54ECF-9A6A-4D3E-9F1F-3FE5B5A4BB8C

P31

Q45086553-839386C2-0240-453B-89E8-4DAFD134D402

P356

Q45086553-FC8A6958-4034-48A0-A362-4D57C8468C98

P407

Q45086553-FF5EE20B-F5C5-4ED6-A487-B54A1FC24BBE

P433

Q45086553-BEFE474E-5545-4452-838D-7F7576ABA736

P478

Q45086553-1CA47823-E372-4C94-97A6-C1E880A21008

P50

Q45086553-D891F92F-C37F-4708-862D-481ABA51CB3B

Q45086553-E262CF2A-69C0-478D-9282-A88F734BAA13

P577

Q45086553-AC1F2111-3A4D-4D96-84BD-7D2948FD2513

P5875

Q45086553-6157D3AF-B0FA-4B07-88E4-1D9652D9B6C8

P698

Q45086553-79AE15F2-0983-498C-AEF4-1A041092DF51

P921

Q45086553-5B3D8E7A-CBD3-4EE5-A7CA-DBFF5C178006

P356

JCO.2004.11.020

P1433

Journal of Clinical Oncology

P1476

Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.

@en

P2093

Gary L Rosner

http://www.w3.org/2001/XMLSchema#string

John T Sandlund

http://www.w3.org/2001/XMLSchema#string

Mary V Relling

http://www.w3.org/2001/XMLSchema#string

Michael Neel

http://www.w3.org/2001/XMLSchema#string

Raul Ribeiro

http://www.w3.org/2001/XMLSchema#string

Scott Howard

http://www.w3.org/2001/XMLSchema#string

Soma Das

http://www.w3.org/2001/XMLSchema#string

Sue C Kaste

http://www.w3.org/2001/XMLSchema#string

Wenjian Yang

http://www.w3.org/2001/XMLSchema#string

P304

3930-3936

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2004.11.020

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8256743

http://www.w3.org/2001/XMLSchema#string

P698

15459215

http://www.w3.org/2001/XMLSchema#string

P921